Blue Owl Capital Shares Up 0.73% to $9.03
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy OWL?
Mixed options sentiment in Blue Owl Capital (OWL), with shares up 6c, or 0.73%, near $9.03. Options volume relatively light with 20k contracts traded and puts leading calls for a put/call ratio of 2.46, compared to a typical level near 3.01. Implied volatility (IV30) dropped 0.69 near 58.15,in the top quartile of the past year, suggesting an expected daily move of $0.33. Put-call skew flattened, suggesting a modestly bullish tone.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OWL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OWL
Wall Street analysts forecast OWL stock price to rise
15 Analyst Rating
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 9.130
Low
18.00
Averages
21.13
High
28.00
Current: 9.130
Low
18.00
Averages
21.13
High
28.00
About OWL
Blue Owl Capital Inc. is an alternative asset management company. The Company deploys private capital across Credit, GP Strategic Capital and Real Estate platforms on behalf of institutional and private wealth clients. Its product platforms include Credit, GP Strategic Capital and Real Estate. Its credit products offer private financing solutions primarily to upper-middle-market companies. Its credit products are offered through a mix of business development companies, long-dated private funds, managed accounts and collateralized loan obligations. It is focused on acquiring equity stakes in or providing debt financing to private capital firms. Its Real Estate products are focused on acquiring triple net lease real estate occupied by investment-grade or creditworthy tenants. Its Real Estate products are offered through Permanent Capital vehicles, including its real estate investment trusts, and long-dated private funds. It offers asset management services to the insurance industry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Blue Owl Capital Closes Asset Special Opportunities Fund IX Exceeding $2.5 Billion Target
- Funding Commitment Exceeds Expectations: Blue Owl Capital announced the final close of its Asset Special Opportunities Fund IX (ASOF IX) with approximately $2.9 billion in total capital commitments, surpassing its original target of $2.5 billion, indicating strong investor support for asset-based finance.
- Flexible Investment Strategy: ASOF IX employs a flexible investment strategy that allows for dynamic asset allocation throughout changing market cycles, reflecting Blue Owl's continued conviction in asset-based finance as a crucial area of private credit aimed at meeting evolving market needs.
- Significant Team Advantage: The Co-CEOs of Blue Owl emphasized that the depth of experience and unique sourcing network of their team enables them to originate complex transactions with consistency and discipline, thereby maintaining a competitive edge as the market expands and ensuring high-quality asset-backed solutions for investors.
- Risk-Adjusted Returns: The Head of Alternative Credit at Blue Owl noted that ASOF IX will support the firm's focus on capturing attractive risk-adjusted returns across various market environments while maintaining strict controls on underwriting and risk management to ensure durable income generation.
See More
Blue Owl Capital Closes Asset Special Opportunities Fund IX Exceeding $2.5 Billion Target
- Capital Commitments Surpassed: Blue Owl Capital announced the successful close of its Asset Special Opportunities Fund IX (ASOF IX) with approximately $2.9 billion in total capital commitments, exceeding the original target of $2.5 billion, reflecting strong investor support for asset-based finance.
- Flexible Investment Strategy: ASOF IX employs a diversified, asset-backed opportunistic strategy that allows for dynamic capital allocation throughout changing market cycles, demonstrating Blue Owl's continued conviction in asset-based finance to meet evolving market needs.
- Significant Team Advantage: The Co-CEOs of Blue Owl highlighted that the depth of experience and unique sourcing network enable the firm to originate complex transactions with consistency and discipline, thereby maintaining a competitive edge in an expanding market and ensuring high-quality asset-backed solutions for investors.
- Risk-Adjusted Returns Focus: The Head of Alternative Credit at Blue Owl stated that ASOF IX will support the firm's focus on capturing attractive risk-adjusted returns across various market environments while maintaining a disciplined approach to underwriting and risk management to ensure durable income generation.
See More
Mortgage Stocks Surge 30% After Ackman's Remarks
- Mortgage Stocks Rally: Shares of Fannie Mae and Freddie Mac surged over 30% on Monday after billionaire Bill Ackman labeled them as 'stupidly cheap' in a social media post, indicating strong market confidence in their future potential.
- Boston Scientific Downgrade: Boston Scientific's stock fell more than 9% after Raymond James downgraded it from strong buy to outperform, reflecting concerns over weakening trends in its key growth areas and leading investors to adopt a cautious stance on its future performance.
- Cybersecurity Gains: Palo Alto Networks saw its shares jump over 7% after CEO Nikesh Arora disclosed a $10 million stock purchase, demonstrating market confidence in the company's growth prospects amid rising demand for cybersecurity solutions.
- United Therapeutics Innovation: United Therapeutics' stock rose nearly 13%, reaching a 52-week high, following positive phase 3 clinical trial results for its main product Tyvaso, and its plan to seek priority FDA review to expand the drug's label, showcasing strategic advancements in lung disease treatment.
See More
Blue Owl's Risk/Reward Profile Appears Exceptionally Favorable
Current Stock Performance: Blue Owl Capital's shares are trading around $9, down over 65% from last year's highs, raising concerns about the company's stability in the private credit space amid a challenging market environment.
Investor Sentiment: There is growing investor wariness regarding potential defaults and liquidity tightening, leading to significant sell-offs in Blue Owl's stock, despite some analysts suggesting that the market may have overreacted to recent performance issues.
Analyst Ratings: Recent shifts in analyst sentiment have turned bullish, with firms like BMO Capital Markets and TD Cowen reiterating buy-equivalent ratings, indicating a belief in the company's long-term stability and growth potential.
Earnings and Dividends: Blue Owl's earnings visibility is bolstered by its fee-based model, and it has a strong track record of dividend increases, making it an attractive option for income-focused investors despite current market volatility.
See More
Blue Owl Capital Raises $20.7 Million Through Private Share Sale
- Private Capital Raise: Blue Owl Capital raised $20.7 million by selling 2.27 million unregistered Class I shares, which supports its public fundraising efforts and demonstrates the firm's proactive approach to expanding its lending portfolio.
- Total Fundraising: Since its inception, Blue Owl has raised over $22 billion across various private offerings and share classes, indicating strong performance in the private credit market and its ability to continuously attract investors.
- Portfolio Structure: As of February 28, Blue Owl's portfolio includes debt investments in 347 companies with a total par value of $34.2 billion, with 87.8% of investments being first-lien debt, reflecting its strategic focus on risk management.
- Liquidity Management: Blue Owl holds approximately $3.9 billion in level 2 liquid assets and $780 million in cash, providing ample liquidity for operations and investor activities, ensuring income generation capabilities amid rising interest rates.
See More
Medallia's Challenges Pose Risks for Private Credit, Affecting Blackstone and Thoma Bravo.
- Medallia's Market Position: Medallia is identified as a significant issue within the private credit markets, highlighting its challenges and vulnerabilities.
- Exposure of Firms: Two firms are noted to have the most exposure to Medallia, indicating potential risks for their financial stability.
See More
Blue Owl Capital Closes Asset Special Opportunities Fund IX Exceeding $2.5 Billion Target
- Funding Commitment Exceeds Expectations: Blue Owl Capital announced the final close of its Asset Special Opportunities Fund IX (ASOF IX) with approximately $2.9 billion in total capital commitments, surpassing its original target of $2.5 billion, indicating strong investor support for asset-based finance.
- Flexible Investment Strategy: ASOF IX employs a flexible investment strategy that allows for dynamic asset allocation throughout changing market cycles, reflecting Blue Owl's continued conviction in asset-based finance as a crucial area of private credit aimed at meeting evolving market needs.
- Significant Team Advantage: The Co-CEOs of Blue Owl emphasized that the depth of experience and unique sourcing network of their team enables them to originate complex transactions with consistency and discipline, thereby maintaining a competitive edge as the market expands and ensuring high-quality asset-backed solutions for investors.
- Risk-Adjusted Returns: The Head of Alternative Credit at Blue Owl noted that ASOF IX will support the firm's focus on capturing attractive risk-adjusted returns across various market environments while maintaining strict controls on underwriting and risk management to ensure durable income generation.
See More
Blue Owl Capital Closes Asset Special Opportunities Fund IX Exceeding $2.5 Billion Target
- Capital Commitments Surpassed: Blue Owl Capital announced the successful close of its Asset Special Opportunities Fund IX (ASOF IX) with approximately $2.9 billion in total capital commitments, exceeding the original target of $2.5 billion, reflecting strong investor support for asset-based finance.
- Flexible Investment Strategy: ASOF IX employs a diversified, asset-backed opportunistic strategy that allows for dynamic capital allocation throughout changing market cycles, demonstrating Blue Owl's continued conviction in asset-based finance to meet evolving market needs.
- Significant Team Advantage: The Co-CEOs of Blue Owl highlighted that the depth of experience and unique sourcing network enable the firm to originate complex transactions with consistency and discipline, thereby maintaining a competitive edge in an expanding market and ensuring high-quality asset-backed solutions for investors.
- Risk-Adjusted Returns Focus: The Head of Alternative Credit at Blue Owl stated that ASOF IX will support the firm's focus on capturing attractive risk-adjusted returns across various market environments while maintaining a disciplined approach to underwriting and risk management to ensure durable income generation.
See More
Mortgage Stocks Surge 30% After Ackman's Remarks
- Mortgage Stocks Rally: Shares of Fannie Mae and Freddie Mac surged over 30% on Monday after billionaire Bill Ackman labeled them as 'stupidly cheap' in a social media post, indicating strong market confidence in their future potential.
- Boston Scientific Downgrade: Boston Scientific's stock fell more than 9% after Raymond James downgraded it from strong buy to outperform, reflecting concerns over weakening trends in its key growth areas and leading investors to adopt a cautious stance on its future performance.
- Cybersecurity Gains: Palo Alto Networks saw its shares jump over 7% after CEO Nikesh Arora disclosed a $10 million stock purchase, demonstrating market confidence in the company's growth prospects amid rising demand for cybersecurity solutions.
- United Therapeutics Innovation: United Therapeutics' stock rose nearly 13%, reaching a 52-week high, following positive phase 3 clinical trial results for its main product Tyvaso, and its plan to seek priority FDA review to expand the drug's label, showcasing strategic advancements in lung disease treatment.
See More
Blue Owl's Risk/Reward Profile Appears Exceptionally Favorable
Current Stock Performance: Blue Owl Capital's shares are trading around $9, down over 65% from last year's highs, raising concerns about the company's stability in the private credit space amid a challenging market environment.
Investor Sentiment: There is growing investor wariness regarding potential defaults and liquidity tightening, leading to significant sell-offs in Blue Owl's stock, despite some analysts suggesting that the market may have overreacted to recent performance issues.
Analyst Ratings: Recent shifts in analyst sentiment have turned bullish, with firms like BMO Capital Markets and TD Cowen reiterating buy-equivalent ratings, indicating a belief in the company's long-term stability and growth potential.
Earnings and Dividends: Blue Owl's earnings visibility is bolstered by its fee-based model, and it has a strong track record of dividend increases, making it an attractive option for income-focused investors despite current market volatility.
See More
Blue Owl Capital Raises $20.7 Million Through Private Share Sale
- Private Capital Raise: Blue Owl Capital raised $20.7 million by selling 2.27 million unregistered Class I shares, which supports its public fundraising efforts and demonstrates the firm's proactive approach to expanding its lending portfolio.
- Total Fundraising: Since its inception, Blue Owl has raised over $22 billion across various private offerings and share classes, indicating strong performance in the private credit market and its ability to continuously attract investors.
- Portfolio Structure: As of February 28, Blue Owl's portfolio includes debt investments in 347 companies with a total par value of $34.2 billion, with 87.8% of investments being first-lien debt, reflecting its strategic focus on risk management.
- Liquidity Management: Blue Owl holds approximately $3.9 billion in level 2 liquid assets and $780 million in cash, providing ample liquidity for operations and investor activities, ensuring income generation capabilities amid rising interest rates.
See More
Medallia's Challenges Pose Risks for Private Credit, Affecting Blackstone and Thoma Bravo.
- Medallia's Market Position: Medallia is identified as a significant issue within the private credit markets, highlighting its challenges and vulnerabilities.
- Exposure of Firms: Two firms are noted to have the most exposure to Medallia, indicating potential risks for their financial stability.
See More
